Abbott Laboratories (ABT) – Apple’s glucose device may affect ABT

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Abbott Laboratories (ABT) (Q1FY23)

Highlights

Abbott Laboratories reported strong organic sales growth in the first quarter, with a 10% increase when excluding the impact of exchange rates, the exit from the pediatric nutrition
business in China, and declining Covid test sales.

ABT experienced 14.8% decrease in total net sales during Q1FY23, excluding the impact of foreign exchange, reflected the decrease in demand for Abbott’s rapid diagnostic tests
to detect COVID-19, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled ~$730mn during the first quarter of 2023 and ~$3.3bn during the first quarter of 2022.

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates